Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 931150 | ISIN: NO0010000045 | Ticker-Symbol: PHS
Frankfurt
01.11.24
08:04 Uhr
4,240 Euro
+0,020
+0,47 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
PHOTOCURE ASA Chart 1 Jahr
5-Tage-Chart
PHOTOCURE ASA 5-Tage-Chart
RealtimeGeldBriefZeit
4,1404,30513:04
4,2204,26001.11.

Aktuelle News zur PHOTOCURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.09.Photocure ASA: Photocure Partner Asieris Unveils Cevira Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting4
30.09.Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting400OSLO, Norway, Sept. 30, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated that international...
► Artikel lesen
27.09.Photocure establishes Named Patient Program to provide access to Hexvix in South Africa302OSLO, Norway, Sept. 27, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it entered into an agreement with Equity Pharmaceuticals PTY Limited, part...
► Artikel lesen
27.09.Photocure ASA: Photocure establishes Named Patient Program to provide access to Hexvix in South Africa2
17.09.Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference649OSLO, Norway, Sept. 17, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today...
► Artikel lesen
17.09.Photocure ASA: Cevira: Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference4
16.09.Photocure ASA: Notification of major shareholding9
08.08.Photocure ASA reports Q2 results3
07.08.PHOTOCURE ASA Bottom Line Rises In Q2-
07.08.Photocure ASA: Results for the second quarter of 2024235OSLO, Norway, Aug. 7, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, today reported Hexvix®/Cysview® revenues of NOK 122.4 million in the second quarter of 2024...
► Artikel lesen
31.07.Photocure ASA: Invitation to presentation of second quarter and first half year 2024 financial results1
15.07.Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization496OSLO, Norway, July 15, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has entered into a strategic agreement with Richard Wolf GmbH to...
► Artikel lesen
15.07.Photocure ASA: Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization1
04.06.Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.391OSLO, Norway, June 4, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has commenced activities to support a new initiative enabling U.S....
► Artikel lesen
04.06.Photocure ASA: Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.2
23.05.Photocure ASA - Annual general meeting held290OSLO, Norway, May 23, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), held its annual general meeting on 23 May 2024 at 17:00 hours (CEST). The minutes from the general meeting setting...
► Artikel lesen
15.05.Photocure ASA reports Q1 results2
15.05.Photocure ASA: Results for the first quarter of 2024366OSLO, Norway, May 15, 2024 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 116.8 million in the first quarter of 2024 (Q1 2023: NOK 105.9 million)...
► Artikel lesen
13.05.Photocure: Asieris' NDA For Cevira Accepted By NMPA For Regulatory Review In China1
12.05.Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China863OSLO, Norway, May 12, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the...
► Artikel lesen
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1